Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Agenus Inc (NQ: AGEN )

3.280 USD -0.115 (-3.39%)
Streaming Delayed Price Updated: 11:11 AM EST, Mar 4, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Agenus Inc

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2020 Financial Report
Conference Call on Monday, March 15, 2021 at 8:30 a.m. ET 
From GlobeNewswire News Releases
Andy Hurley Named Agenus Chief Commercial Officer
From GlobeNewswire News Releases
Agenus Announces Agenus Insights - Virtual R&D Miniseries
From GlobeNewswire News Releases
Agenus Announces New Responses for AGEN1181
From GlobeNewswire News Releases
Thinking about buying stock in Canopy Growth Corp, 3D Systems, Bilibili, Agenus, or Vyne Therapeutics?
InvestorsObserver issues critical PriceWatch Alerts for CGC, DDD, BILI, AGEN, and VYNE. 
From PR Newswire
Agenus Announces Positive Preliminary Results of iNKT Cell Therapy Trial in COVID-19
From GlobeNewswire News Releases
Agenus Enters into Clinical Collaboration with Nelum for Zalifrelimab Combination
From GlobeNewswire News Releases
Agenus to Participate in B. Riley Securities' Oncology Investor Conference
From GlobeNewswire News Releases
Completion of Balstilimab BLA Filing Extended To 1H2021
Agenus to fulfill FDA feedback for six-month follow-up on late responders 
From GlobeNewswire News Releases
Agenus Launches Phase 2 Trial Expansion in Colon Cancer for AGEN1181 in Combination with Balstilimab
New objective response in colon cancer triggers trial expansion 
From GlobeNewswire News Releases
Agenus to Participate in Evercore ISI 3rd Annual HealthCONx Conference
From GlobeNewswire News Releases
VBI Vaccines Announces Positive Interim Phase 2a Data from VBI-1901 in Recurrent GBM
VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI") a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced Phase 2a (Part B) data... 
From Business Wire News Releases
Agenus to Participate in Fireside Chat at the Jefferies 2020 Virtual London Healthcare Conference
From GlobeNewswire News Releases
Agenus and Dr. Steven O’Day to Participate in Webcast Hosted by William Blair on AGEN1181 and SITC Data
From GlobeNewswire News Releases
Agenus and Dr. Steven O’Day to Participate in Panels at the Virtual SITC 2020 Immuno-Oncology Event Hosted by B. Riley
From GlobeNewswire News Releases
XOMA Earns First Milestone Payment from 2018 Royalty Purchase Agreement
From GlobeNewswire News Releases
An Agenus-discovered first-in-class ILT4 antibody, MK-4830, enters Phase 2
From GlobeNewswire News Releases
Agenus Presents Additional Clinical Responses and Novel Biomarker Data at SITC2020
From GlobeNewswire News Releases
Dr. Steven O’Day Named Agenus Chief Medical Officer
Immunotherapy Pioneer to Join As Company Ramps Up Commercialization and NextGen Clinical Pipeline Efforts 
From GlobeNewswire News Releases
Agenus Doses First COVID-19 Patient with iNKT Cell Therapy
From GlobeNewswire News Releases
Agenus R&D Update & Third Quarter Financial Report
From GlobeNewswire News Releases
Agenus to Report Third Quarter Earnings
Conference Call and Webcast on Thursday, October 29, 2020 from 8:30 – 9:30 am 
From GlobeNewswire News Releases
Agenus to Present on Seven Novel Programs at SITC 2020
From GlobeNewswire News Releases
Susan Hirsch Joins Agenus’ Board of Directors
From GlobeNewswire News Releases
Agenus Initiates Rolling BLA Submission of Balstilimab for Recurrent/Metastatic Cervical Cancer
From GlobeNewswire News Releases
Agenus Presents Results from Two Large Cervical Cancer Trials at ESMO
From GlobeNewswire News Releases
Dr. Jennifer Buell Speaks Live at Scientific American Inaugural Fireside Chat Series 18 Minutes With
From GlobeNewswire News Releases
Agenus to Participate in Webcast Hosted by William Blair on ESMO2020 Results and Novel Pipeline
From GlobeNewswire News Releases
Thinking about buying stock in Avinger, Vascular Biogenics, Intra-Cellular Therapies, Agenus, or Co-Diagnostics?
InvestorsObserver issues critical PriceWatch Alerts for AVGR, VBLT, ITCI, AGEN, and CODX. 
From PR Newswire
Paul Clark Joins Agenus Board of Directors
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and... 
From PR Newswire
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.